Vimian Group (VIMIAN) Aandelenoverzicht
Vimian Group AB (publ) houdt zich wereldwijd bezig met diergezondheid. Meer informatie
| Sneeuwvlok Score | |
|---|---|
| Waardering | 2/6 |
| Toekomstige groei | 4/6 |
| Prestaties in het verleden | 4/6 |
| Financiële gezondheid | 4/6 |
| Dividenden | 0/6 |
Beloningen
Risicoanalyse
Geen risico's gedetecteerd voor VIMIAN uit onze risicocontroles.
VIMIAN Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Vimian Group AB (publ) Concurrenten
Prijsgeschiedenis en prestaties
| Historische aandelenkoersen | |
|---|---|
| Huidige aandelenkoers | SEK 28.25 |
| 52 Week Hoogtepunt | SEK 46.00 |
| 52 Week Laag | SEK 24.18 |
| Bèta | 1.19 |
| 1 maand verandering | -0.70% |
| 3 maanden verandering | 4.86% |
| 1 Jaar Verandering | -32.32% |
| 3 jaar verandering | -0.74% |
| 5 jaar verandering | n/a |
| Verandering sinds IPO | -65.08% |
Recent nieuws en updates
Narratiefupdate • May 06
VIMIAN: Margin Execution And Governance Changes Will Support Future Upside Potential
Analysts now see fair value for Vimian Group at about SEK 35, up from roughly SEK 34, even though the latest Street research includes a reduced price target to SEK 25 from SEK 27. This reflects updated views on revenue growth, margins, the appropriate discount rate and future P/E assumptions.
Narratiefupdate • Apr 17
VIMIAN: Higher Discount Rate Will Constrain Future Upside Potential
Analysts have trimmed their price target on Vimian Group to SEK 25 from SEK 27, reflecting updated views on discount rates, growth and profitability assumptions. Analyst Commentary Bearish analysts are signaling a more cautious stance on Vimian Group, with the latest move being a reduction in the price target to SEK 25 from SEK 27.Narratiefupdate • Apr 03
VIMIAN: Margin Execution And New Bylaws Will Support Future Upside Potential
Analysts have reduced their price target for Vimian Group to SEK 25 from SEK 27, citing updated assumptions on margins and valuation multiples that result in a slightly adjusted fair value model. Analyst Commentary Recent research points to a more cautious stance on Vimian Group, with the updated SEK 25 price target reflecting revised assumptions on margins and valuation multiples rather than a shift in rating.Recent updates
Narratiefupdate • May 06
VIMIAN: Margin Execution And Governance Changes Will Support Future Upside Potential
Analysts now see fair value for Vimian Group at about SEK 35, up from roughly SEK 34, even though the latest Street research includes a reduced price target to SEK 25 from SEK 27. This reflects updated views on revenue growth, margins, the appropriate discount rate and future P/E assumptions.Narratiefupdate • Apr 17
VIMIAN: Higher Discount Rate Will Constrain Future Upside Potential
Analysts have trimmed their price target on Vimian Group to SEK 25 from SEK 27, reflecting updated views on discount rates, growth and profitability assumptions. Analyst Commentary Bearish analysts are signaling a more cautious stance on Vimian Group, with the latest move being a reduction in the price target to SEK 25 from SEK 27.Narratiefupdate • Apr 03
VIMIAN: Margin Execution And New Bylaws Will Support Future Upside Potential
Analysts have reduced their price target for Vimian Group to SEK 25 from SEK 27, citing updated assumptions on margins and valuation multiples that result in a slightly adjusted fair value model. Analyst Commentary Recent research points to a more cautious stance on Vimian Group, with the updated SEK 25 price target reflecting revised assumptions on margins and valuation multiples rather than a shift in rating.Narratiefupdate • Mar 20
VIMIAN: Lower Price Outlook And Execution Risks Will Shape Fair Value Balance
Analysts have trimmed their price target for Vimian Group to SEK 25 from SEK 27, citing updated assumptions on growth, margins and valuation multiples that align the target more closely with recent research views. Analyst Commentary Recent research reflects a cautious tone around Vimian Group, with the latest move being a trim in the price target to SEK 25 from SEK 27.Narratiefupdate • Mar 05
VIMIAN: Reduced Price Outlook And Execution Risks Will Shape Fairly Balanced Prospects
Analysts have lowered their price target on Vimian Group to SEK 25 from SEK 27, reflecting updated assumptions for fair value, discount rate, revenue growth, profit margin and future P/E multiples. Analyst Commentary Bearish analysts have trimmed their fair value assumptions for Vimian Group, as seen in the reduced price target to SEK 25 from SEK 27.
Narratiefupdate • Feb 19
VIMIAN: Reset Expectations Will Highlight Execution Under New CEO Appointment
Analysts have trimmed their fair value estimate and price target on Vimian Group to SEK 27 from SEK 37, reflecting updated assumptions around slightly higher growth, a lower profit margin profile and a higher expected P/E multiple, which together point to a more cautious risk return trade off. Analyst Commentary Bullish analysts looking at Vimian Group are focusing less on the headline downgrade and more on what the revised SEK 27 target implies for execution, valuation and growth expectations from here.Analyseartikel • Feb 16
Vimian Group AB (publ) (STO:VIMIAN) Just Reported Annual Earnings: Have Analysts Changed Their Mind On The Stock?
Investors in Vimian Group AB (publ) ( STO:VIMIAN ) had a good week, as its shares rose 5.9% to close at kr27.84...Analyseartikel • Feb 05
Is Vimian Group (STO:VIMIAN) Using Too Much Debt?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Narratiefupdate • Feb 05
VIMIAN: Future Leadership Change Will Support Execution Upside Despite Sector Downgrade
Narrative update Analysts have trimmed their price expectations for Vimian Group, with the updated fair value estimate easing from SEK 36.92 to SEK 33.76, as some now see lower future P/E assumptions and have adopted more cautious views similar to the recent SEK 27 price target cut in Street research. Analyst Commentary Recent research updates on Vimian Group have taken a more cautious tone, with the shift to an Underweight rating and a price target of SEK 27, down from SEK 37.Narratiefupdate • Jan 22
VIMIAN: Rebased Expectations Will Spotlight Execution Under New Leadership Transition Narrative
Analysts have reduced their fair value estimate for Vimian Group to SEK 41.36 from SEK 41.97, citing slightly higher discount rate assumptions and updated sector views. This follows a recent cut in the Street price target to SEK 27 from SEK 37.Narratiefupdate • Jan 08
VIMIAN: Rebased Expectations Will Highlight Execution On M&A-Led Expansion Narrative
Analysts have lowered their fair value estimate for Vimian Group from SEK 51.65 to SEK 41.97, citing more cautious assumptions on revenue growth and valuation multiples in line with recent price target cuts, including the move to SEK 27 from SEK 37 in Barclays' 2026 industry outlook. Analyst Commentary Recent research points to a more cautious stance on Vimian Group, with fair value and price targets recalibrated to reflect updated assumptions on revenue growth and sector valuation.Analyseartikel • Jan 08
Returns On Capital Are Showing Encouraging Signs At Vimian Group (STO:VIMIAN)
There are a few key trends to look for if we want to identify the next multi-bagger. One common approach is to try and...Narratiefupdate • Dec 23
VIMIAN: Downgrade And New CEO Will Shape Medium Term Risk Outlook
Analysts have lowered their price target on Vimian Group from approximately SEK 37 to around SEK 27. This reflects more cautious assumptions on growth, profitability, and valuation multiples in line with a more conservative sector outlook for 2026.Narratiefupdate • Dec 09
VIMIAN: Future Leadership Will Drive Cash Flow Execution Upside Despite Sector Downgrade
Analysts have trimmed their price target on Vimian Group by SEK 10 to SEK 27. This reflects slightly higher discount rate assumptions and more conservative long term valuation multiples for the sector.Narratiefupdate • Nov 25
VIMIAN: Future Leadership and Expanded Acquisitions Will Drive Market Resilience
Narrative Update on Vimian Group Analysts have lowered Vimian Group's fair value estimate from SEK 38.90 to SEK 36.97. This revision is attributed to reduced revenue growth expectations, a higher discount rate, and a more cautious industry outlook reflected in recent research.Analyseartikel • Sep 10
Vimian Group AB (publ)'s (STO:VIMIAN) Intrinsic Value Is Potentially 40% Above Its Share Price
Key Insights The projected fair value for Vimian Group is kr43.69 based on 2 Stage Free Cash Flow to Equity Vimian...Narratiefupdate • Sep 05
Digital Adoption And Niche Expansion Will Empower Veterinary Healthcare
Ongoing execution challenges in MedTech, anticipated organic growth slowing to 5% in 2025, and required recovery in orthopedics have led analysts to adopt a more cautious outlook and maintain Vimian Group's price target at SEK38.90. Analyst Commentary Ongoing execution challenges in the MedTech segment are impacting overall group momentum.Analyseartikel • Aug 14
Vimian Group AB (publ) (STO:VIMIAN) Shares Slammed 26% But Getting In Cheap Might Be Difficult Regardless
OM:VIMIAN 1 Year Share Price vs Fair Value Explore Vimian Group's Fair Values from the Community and select yours...Analyseartikel • Jun 17
If EPS Growth Is Important To You, Vimian Group (STO:VIMIAN) Presents An Opportunity
Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...Analyseartikel • Jun 02
Estimating The Intrinsic Value Of Vimian Group AB (publ) (STO:VIMIAN)
Key Insights Vimian Group's estimated fair value is kr55.41 based on 2 Stage Free Cash Flow to Equity Vimian Group's...Analyseartikel • May 15
Getting In Cheap On Vimian Group AB (publ) (STO:VIMIAN) Is Unlikely
With a median price-to-sales (or "P/S") ratio of close to 4.6x in the Medical Equipment industry in Sweden, you could...Analyseartikel • Mar 05
Is Vimian Group (STO:VIMIAN) A Risky Investment?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Analyseartikel • Feb 21
Vimian Group's (STO:VIMIAN) Earnings Are Weaker Than They Seem
Unsurprisingly, Vimian Group AB (publ)'s ( STO:VIMIAN ) stock price was strong on the back of its healthy earnings...Analyseartikel • Feb 14
A Look At The Fair Value Of Vimian Group AB (publ) (STO:VIMIAN)
Key Insights The projected fair value for Vimian Group is kr54.92 based on 2 Stage Free Cash Flow to Equity Current...
Nieuw narratief • Feb 09
iM3 Acquisition Will Expand Presence In Veterinary Dental Space
Expansion in Specialty Pharma and strategic focus on cash generation are expected to drive organic growth, enhancing revenue and margins.Analyseartikel • Dec 16
Returns On Capital Are Showing Encouraging Signs At Vimian Group (STO:VIMIAN)
If we want to find a potential multi-bagger, often there are underlying trends that can provide clues. Amongst other...Analyseartikel • Aug 31
Revenues Not Telling The Story For Vimian Group AB (publ) (STO:VIMIAN) After Shares Rise 27%
Vimian Group AB (publ) ( STO:VIMIAN ) shareholders have had their patience rewarded with a 27% share price jump in the...Analyseartikel • Aug 17
Is Vimian Group (STO:VIMIAN) A Risky Investment?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...Analyseartikel • Apr 18
Vimian Group (STO:VIMIAN) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of
Vimian Group AB (publ)'s ( STO:VIMIAN ) robust earnings report didn't manage to move the market for its stock. Our...Analyseartikel • Apr 09
Vimian Group AB (publ) (STO:VIMIAN) Shares Could Be 40% Below Their Intrinsic Value Estimate
Key Insights Using the 2 Stage Free Cash Flow to Equity, Vimian Group fair value estimate is kr55.14 Vimian Group's...Analyseartikel • Feb 13
Vimian Group (STO:VIMIAN) Is Experiencing Growth In Returns On Capital
Did you know there are some financial metrics that can provide clues of a potential multi-bagger? One common approach...Analyseartikel • Jan 08
Little Excitement Around Vimian Group AB (publ)'s (STO:VIMIAN) Revenues
Vimian Group AB (publ)'s ( STO:VIMIAN ) price-to-sales (or "P/S") ratio of 3.6x might make it look like a buy right now...Analyseartikel • Dec 03
Why Vimian Group AB (publ) (STO:VIMIAN) Could Be Worth Watching
While Vimian Group AB (publ) ( STO:VIMIAN ) might not be the most widely known stock at the moment, it saw a...Analyseartikel • Nov 01
There's Been No Shortage Of Growth Recently For Vimian Group's (STO:VIMIAN) Returns On Capital
If we want to find a potential multi-bagger, often there are underlying trends that can provide clues. Firstly, we'll...Rendement voor aandeelhouders
| VIMIAN | SE Medical Equipment | SE Markt | |
|---|---|---|---|
| 7D | -5.0% | 3.8% | 2.9% |
| 1Y | -32.3% | -5.7% | 13.1% |
Rendement versus industrie: VIMIAN presteerde slechter dan de Swedish Medical Equipment -sector, die het afgelopen jaar een rendement van -5.7 % opleverde.
Rendement versus markt: VIMIAN presteerde slechter dan Swedish Market, dat het afgelopen jaar een rendement van 13.1 % opleverde.
Prijsvolatiliteit
| VIMIAN volatility | |
|---|---|
| VIMIAN Average Weekly Movement | 4.7% |
| Medical Equipment Industry Average Movement | 7.5% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in SE Market | 13.4% |
| 10% least volatile stocks in SE Market | 3.7% |
Stabiele aandelenkoers: VIMIAN heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend vergeleken met de Swedish markt.
Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 5% ) van VIMIAN is het afgelopen jaar stabiel geweest.
Over het bedrijf
| Opgericht | Werknemers | CEO | Website |
|---|---|---|---|
| 2020 | 1,300 | Alireza Tajbakhsh | vimian.com |
Vimian Group AB (publ) houdt zich wereldwijd bezig met diergezondheid. Het bedrijf is actief in de segmenten Specialty Pharma, MedTech, Diagnostics en Veterinary Services. Het bedrijf biedt eigen diagnostica, behandelingen op recept en behandelingen zonder recept voor preventieve zorg en behandeling van chronische aandoeningen voor gezelschapsdieren onder de merknaam Nextmune; en moleculaire en immunodiagnostische oplossingen die worden gebruikt door laboratoria voor veterinaire specifieke toepassingen met een focus op de markten voor vee en gezelschapsdieren onder de merknaam Indical Bioscience.
Vimian Group AB (publ) Samenvatting
| VIMIAN fundamentele statistieken | |
|---|---|
| Marktkapitalisatie | SEK 14.95b |
| Inkomsten(TTM) | SEK 398.16m |
| Inkomsten(TTM) | SEK 4.69b |
37.6x
Koers/Winstverhouding3.2x
P/S-verhoudingIs VIMIAN overgewaardeerd?
Zie Reële waarde en waarderingsanalyseInkomsten en omzet
| VIMIAN resultatenrekening (TTM) | |
|---|---|
| Inkomsten | €433.60m |
| Kosten van inkomsten | €134.40m |
| Brutowinst | €299.20m |
| Overige uitgaven | €262.40m |
| Inkomsten | €36.80m |
Laatst gerapporteerde inkomsten
Mar 31, 2026
Volgende inkomensdatum
Jul 17, 2026
| Winst per aandeel (EPS) | 0.07 |
| Brutomarge | 69.00% |
| Nettowinstmarge | 8.49% |
| Schuld/Eigen Vermogen Verhouding | 31.5% |
Hoe presteerde VIMIAN op de lange termijn?
Bekijk historische prestaties en vergelijkingBedrijfsanalyse en status van financiële gegevens
| Gegevens | Laatst bijgewerkt (UTC-tijd) |
|---|---|
| Bedrijfsanalyse | 2026/05/26 07:06 |
| Aandelenkoers aan het einde van de dag | 2026/05/26 00:00 |
| Inkomsten | 2026/03/31 |
| Jaarlijkse inkomsten | 2025/12/31 |
Gegevensbronnen
De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.
| Pakket | Gegevens | Tijdframe | Voorbeeld Amerikaanse bron * |
|---|---|---|---|
| Financiële gegevens bedrijf | 10 jaar |
| |
| Consensus schattingen analisten | +3 jaar |
|
|
| Marktprijzen | 30 jaar |
| |
| Eigendom | 10 jaar |
| |
| Beheer | 10 jaar |
| |
| Belangrijkste ontwikkelingen | 10 jaar |
|
* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.
Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.
Analysemodel en Snowflake
Details van het analysemodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina. We hebben ook handleidingen over hoe je onze rapporten kunt gebruiken en tutorials op YouTube.
Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.
Industrie en sector
Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.
Bronnen van analisten
Vimian Group AB (publ) wordt gevolgd door 10 analisten. 5 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.
| Analist | Instelling |
|---|---|
| null null | ABG Sundal Collier |
| Jonathon Unwin | Barclays |
| Kristofer Liljeberg-Svensson | Carnegie Investment Bank AB |